First-Ever Large-Scale Prospective Study in Hispanic Patients With Elevated Cholesterol Demonstrates Significant Cholesterol Re
March 24 2006 - 8:00AM
PR Newswire (US)
WASHINGTON, March 24 /PRNewswire-FirstCall/ -- New data presented
today at the National Hispanic Medical Association (NHMA) annual
meeting showed that AstraZeneca's CRESTOR(R) (rosuvastatin calcium)
at 10 and 20 mg reduced LDL-C or "bad" cholesterol by 45.2 and 50.0
percent, compared to 35.9 and 42.4 percent with atorvastatin at
milligram-equivalent doses in Hispanic patients with elevated
cholesterol (p